Skip to main content

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.

Publication ,  Journal Article
Giordano, SH; Freedman, RA; Somerfield, MR; Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel
Published in: J Clin Oncol
January 20, 2022

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

Duke Scholars

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

January 20, 2022

Volume

40

Issue

3

Start / End Page

307 / 309

Location

United States

Related Subject Headings

  • Time Factors
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Medical Oncology
  • Humans
  • Female
  • Disease-Free Survival
  • Consensus
  • Chemotherapy, Adjuvant
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Giordano, S. H., Freedman, R. A., Somerfield, M. R., & Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. (2022). Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. J Clin Oncol, 40(3), 307–309. https://doi.org/10.1200/JCO.21.02677
Giordano, Sharon H., Rachel A. Freedman, Mark R. Somerfield, and Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. “Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.J Clin Oncol 40, no. 3 (January 20, 2022): 307–9. https://doi.org/10.1200/JCO.21.02677.
Giordano SH, Freedman RA, Somerfield MR, Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. J Clin Oncol. 2022 Jan 20;40(3):307–9.
Giordano, Sharon H., et al. “Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.J Clin Oncol, vol. 40, no. 3, Jan. 2022, pp. 307–09. Pubmed, doi:10.1200/JCO.21.02677.
Giordano SH, Freedman RA, Somerfield MR, Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. J Clin Oncol. 2022 Jan 20;40(3):307–309.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

January 20, 2022

Volume

40

Issue

3

Start / End Page

307 / 309

Location

United States

Related Subject Headings

  • Time Factors
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Medical Oncology
  • Humans
  • Female
  • Disease-Free Survival
  • Consensus
  • Chemotherapy, Adjuvant